Anavex Life Sciences Corp. (OTCQX: AVXL) is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, other Central Nervous System (CNS) diseases and various types of cancer. All are indications with significant unmet medical needs. SNNLive spoke with Christopher U. Missling, PhD, President & CEO of Anavex Life Sciences Corp. at the SeeThruEquity MicroCap Investor Conference 2014 in New York City, NY.
Dr. Missling begins with an overview of the company, “Anavex is targeting the largest and fastest growing therapeutic area, Alzheimer’s disease.” He adds, “The Company just initiated a Phase 2 clinical trial where we will treat affected patients for the first time. We expect this data to be available in the next year. The Company's drug therapeutic is a small molecule, which in pre-clinical models has been shown not only to reduce stress in the brain, therefore reducing symptoms, but also to be potentially disease modifying.”
He continues with the Company's dedication to Alzheimer’s, “The correlation of aging is so strong that every 5 years, from 65 to 70, one's chances of getting Alzheimer’s doubles, and from 70 to 75 doubles, and again from 75 to 80. There is an element of chronic stress.
Dr. Missling concludes by looking forward to 2015-2016, “The Company aims to capture and maximize key information in the most efficient way with our innovative adaptive trial design, and we would be excited if we could confirm in the outcome of the drug, the positive data we have seen so far. If accomplished, Anavex would potentially engage in a full Phase 3 trial in order to get the drug approved for the treatment of those affected by this devastating disease." For more information, check out their website: www.Anavex.com
© 2017 Stock News Now
Supported by Superior Web Solutions